Bristol-Myers Squibb offered on Thursday to buy the 83 per cent of ImClone it does not already own for $4.5bn, leaving Carl Icahn, the chairman of the biotechnology company, to decide whether to negotiate over a deal.
The $60 a share all-cash offer values ImClone at about $5.2bn and represents a 29 per cent premium to its closing share price on Wednesday.
